dine during high-flux dialysis in non-diabetic (from 9.1±5.1 to 8.5±4.7 pmol/mg protein; P<0.05) and Background. There has been much recent interest in accumulation of advanced glycation end-products diabetic patients (from 10.0±9.1 to 6.8±4.0 pmol/mg protein; P<0.05). In contrast, plasma fructoselysine (AGE ) in uraemic patients. Analysis of AGE has been difficult, because commonly used methodologies, i.e. showed only a non-significant trend to decrease in diabetic (from 3.24±0.88 to 3.05±0.77 nmol/mg proimmunodetection assays or fluorescence measurements, reflect group reactivity and are not specific for chemic-tein) and non-diabetic patients (from 2.69±0.52 to 2.56±0.50 nmol/mg protein). Pyrraline, a nonally defined substances. Some investigators measured individual AGE compounds, e.g. pentosidine, carboxy-fluorescent late AGE product derived from reaction of 3-deoxyglucosone with lysine, could not be detected methyllysine, pyrraline or imidazolone, but a systematic assessment of known compounds using specific (detection limit~40 pmol/mg protein). Comparing HPLC and size exclusion analysis, it was found that HPLC methods in diabetic and non-diabetic end-stage renal disease ( ESRD) patients during treatment has pentosidine accumulated in the range of low molecular weight substances and was removed by high-flux not been performed. Methods. For the present study, the concentrations of dialysis.
Introduction
were found at~70,~14 and <2 kDa, confirming results obtained by other authors. In diabetic patients, the fluorescence intensity of the low molecular weight Since the first description of the reaction, the term fraction was higher. Uraemic patients differed from 'Maillard reaction' stands for a complex series of noncontrols mainly by the fluorescence of the low molecu-enzymatic reactions between reducing sugars (e.g. glular weight fraction. The peak spectrum in ultrafiltrates cose) and amino groups of proteins, peptides or amino was similar to that in plasma regarding low molecular acids [1] . The complexity and variety of the reaction weight fractions and the 14 kDa peak, but no protein-pathways between glucose and amino groups were bound fluorescence was found at 70 kDa. HPLC ana-described in numerous model systems developed in lysis revealed a significant reduction of plasma pentosi-food science because of the importance of heat treatment of sugar and proteins in food processing [2, 3] . It has been established that the concentrations of Correspondence and offprint requests to: Professor Eberhard Ritz, advanced glycation end-products (AGE) increase up Klinikum der Universität Heidelberg, Sektion Nephrologie, Bergheimer Str. 56a, D-69115 Heidelberg, Germany.
to 10-fold during uraemia. This increase is the com-© 1999 European Renal Association-European Dialysis and Transplant Association Heterogeneity of AGE compounds during high-flux dialysis 1969 study patients are given in Table 1 . Plasma taken from bined result of enhanced generation due to oxidative healthy volunteers (n=6, female, 26±2 years) having no or a-dicarbonyl stress [4] [5] [6] on the one hand, and of dietary restrictions served as control. diminished or absent elimination by the kidneys on the other [7] . Only few data are available concerning the effect of chronic haemodialysis on the elimination Treatment modality of chemically defined AGE, presumably because of Maintenance haemodialysis was performed as follows: blood methodical problems caused by the heterogeneity flow 250-300 ml/min; dialysate flow 500 ml/min using bicarof AGE compounds. bonate dialysate; treatment time 5 h; steam-sterilized highOdetti et al. [8] , using HPLC, failed to find effects flux haemodialysers (Polyflux@ 14S, Gambro Dialysatoren, of dialysis on plasma pentosidine levels and, even Hechingen, Germany) containing 1.4 m2 synthetic Polyamide during haemofiltration, reduction was no more than S hollow fibre membranes. Patients had no dietary restric-5%. In contrast, Papanastasiou et al. [9] , using a tions other than reduced potassium and fluid intake. No competitive immunological assay, i.e. solid phase-food and no coffee or tea were ingested during dialysis bound AGE-bovine serum albumin (BSA) and poly-sessions. clonal antibody raised against BSA aged for 3 months, found highly variable effects of haemodialysis on Study design plasma concentrations. The main fraction of AGE was found in the molecular weight range of 1.5-2.0 kDa. EDTA plasma samples were drawn before (i.e.~10 min Friedlander et al. [10, 11] , using HPLC for detection after the start), during (i.e. after 2-2.5 h) and at the end of of protein-bound pentosidine, found a significant cor-dialysis sessions (5 h). They were processed immediately relation between residual renal function and pentosid-according to a strict protocol, i.e. storage of EDTA-blood on ice and centrifugation within 30 min at 4°C, 1500 g for ine concentrations in plasma of undialysed chronic 10 min. Plasma aliquots were taken and stored at −80°C renal failure patients, peritoneal dialysis patients and before analysis.
haemodialysis patients. The highest concentrations For sampling of ultrafiltrate from the dialysate compartwere found for haemodialysis patients. Makita et al.
ment, which was performed immediately after plasma sam- [12] found that in diabetic haemodialysis patients the pling, dialysate tubes were disconnected and the dialysate majority of AGE compounds were in the molecular fluid flushed out while isolated filtration was performed for weight range 2-5 kDa. Significant removal of this 10 min. The first fraction (~100-200 ml ) was discarded and fraction by high-flux membranes was noted. We used 50 ml of filtrate was collected. Aliquots were put on ice immunological detection and were unable to demon-immediately and stored at −80°C before analysis. strate removal of AGE by haemodialysis using regenerated cellulose membranes [13] . Miyata et al. [14] Analytical techniques measured the albumin-bound and free fractions of pentosidine during peritoneal dialysis and haemo-For fluorescence spectroscopy,a spectrofluorimeter (LS 50 B, dialysis. Approximately 80% of free pentosidine was Perkin Elmer, Ü berlingen, Germany) was used at 350 nm removed by haemodialysis using regenerated cellulose excitation and 430 nm emission wavelengths (see figures). membranes, reflecting substantial diffusive permeabil-Emission spectra were obtained at 350 nm excitation and 380-600 nm emission. The use of excitation 350 nm/emission ity of low molecular weight substances, and a rebound 430 nm is based on the spectral fluorescence analysis of to 80% of the pre-dialysis levels was observed within patient plasma and ultrafiltrate. A maximum of absorption 24 h. was found at 350 nm and this wavelenth was therefore chosen
The present study was undertaken to assess the to increase the sensitivity of detection. Maxima of emiselimination of chemically defined Amadori and AGE sion were found at~440 nm and~420 nm in plasma and compounds during high-flux dialysis. A spectrum of ultrafiltrate, respectively. In order to be able to use a single analytical methods was used, i.e. HPLC for fructoselys-wavelength of detection for both plasma and ultrafiltrate ine, pentosidine and pyrraline, and total fluorescence samples, emission was recorded at 430 nm. Plasma samples, and distribution of fluorescence in different molecular but not ultrafiltrate samples, were diluted 1525 or 1550 with weight ranges. We reasoned that simultaneous analysis phosphate-buffered saline (PBS ).
Size-selective gel permeation chromatography (GPC ) of with different methods should provide more complete insights into the elimination kinetics in the hope of developing rational strategies for removal of Maillard plasma and ultrafiltrate samples was performed using an described previously [18] . For pyrraline detection, amino acid analysis was performed as described above with the isocratic HPLC system ( Waters, Eschborn, Germany) equipped with a Superdex 75HR 10/30 column (Amersham combination of the PDA (set at a wavelength of 297 nm) and ninhydrin derivatization [18] . Alternatively, pyrraline Pharmacia Biotech, Freiburg, Germany) eluted at 0.5 ml/min with 10 mM PBS pH 7.2, containing 300 mM NaCl. analysis was performed via isocratic ion-pair reversed-phase HPLC with UV detection [19] . Pyrraline reference material Fluorescence signals (excitation 350 nm; emission 430 nm) were recorded using the LS50B spectrofluorimeter equipped was synthesized according to Henle and Bachmann [20] .
The protein content in plasma and ultrafiltrate samples with a flowthrough cuvette for liquid chromatography. For calibration (i.e. the relationship between molecular weight was analysed using a conventional protein detection assay (Pierce, Rockford, USA) processed according to the manuand retention time), the following proteins (Sigma, Deisenhofen, Germany) were dissolved in eluent buffer as facturer's instructions. Highly purified human albumin (Sigma, Deisenhofen, Germany) was used for calibration of standards: BSA (66 kDa), chicken egg albumin (45 kDa), bovine erythrocyte carbonic anhydrase (29 kDa), horse heart the assay. It is important to note that these methods overestimate protein concentration, especially in the presence of myoglobin (17 kDa) and bovine lung aprotinin (6.5 kDa). The optimal separation range for the column was 70-7 kDa short oligo-or polypeptides. with retention times from 18 to 30 min. Molecular weights of peaks detected in chromatograms of plasma or ultrafiltrate Statistics were assigned according to their retention times using a linear regression curve based on the values found for standard The data were not corrected for haemoconcentration and proteins. The accuracy achieved by this size exclusion method are shown as mean±standard deviation. The RS/1 software is due to the logarithmic calibration characteristics estimated package (release 5.2; BBN Software Products Co., to be in the range of ±20%.
Cambridge, USA) was used for statistical analysis, and Fructoselysine and pentosidine were quantified by amino statistical significance was assumed for P<0.05. Wilcoxon's acid analysis using HPLC after prior acid hydrolysis. Plasma signed rank test and Mann-Whitney U-test were applied for samples (1 ml ) were hydrolysed in 10 ml of 6 M HCl comparison of paired and unpaired data, respectively. A for 23 h at 110°C. After cooling, 1 ml of the hydrolysate linear regression method was used for correlation. was vacuum dried on a Speedvac concentrator (Savent, Formingdale, USA) and dissolved in 200 ml of 0.2 M sodium Results citrate buffer, pH 2.2. Amino acid analysis was performed on an Alpha Plus amino acid analyser (LKB Biochrom, Cambridge, USA), using a stainless steel column Fluorescence in plasma and ultrafiltrate of dialysis (150×4 mm) filled with ion-exchange resin, DC4A-spec patients sodium form (Benson, Reno, Nevada, USA). The composition of elution buffers, ninhydrin reagent as well as the The fluorescence intensity (excitation 350 nm, emission running conditions are described elsewhere [15, 16 ] . Injection 430 nm) yielded by plasma and ultrafiltrate at various volume was 10-80 ml. After separation on the ion-exchange time points of a dialysis session is shown in Figure 1 . column, amino acids were detected initially using a photodi-No significant difference was found when comparode array detector PDA 996 ( Waters, Eschborn, Germany); ing pre-dialysis samples of diabetic and non-diabetic for furosine quantification, a detection wavelength of 280 nm patients. In both groups, a significant exponential was used or a fluorescence detector SFM 25 ( Kontron, decrease by~30% was observed during high-flux The ratio between the fluorescence intensity and fructoselysine was calculated by multiplying the molar furos-protein concentration, calculated for each patient, ine values by the factor 3.1, i.e. the known conversion factor decreases by~30% during treatment (Table 2) .
for the degradation of fructoselysine during acid hydrolysis Analysis of the emission spectra (excitation at [17] . For quantification of pentosidine, reference material 350 nm) showed a shift of the emission maximum was isolated as described [16 ] . Briefly, N-a-acetyllysine, Ntowards higher wavelengths in plasma samples during a-acetylarginine and ribose were incubated for 48 h at 65°C, treatments. This was statistically significant in nonfollowed by acid hydrolysis of the reaction mixture, preparatdiabetic, but not in diabetic patients ( Table 2 ). The ive ion-exchange chromatography and final purification on a semi-preparative reversed-phase HPLC column. The struc-wavelength of the emission maximum was significantly ture and purity of the isolated pentosidine were established (P<0.01) lower in ultrafiltrates than in plasma for with nuclear magnetic resonance, mass spectroscopy and both patient groups and at all sampling times ( Table UV spectroscopy. The pentosidine content was determined 2), indicating heterogeneity of fluorescent substances, via elementary analysis. Based on this, a molar absorptivity with different behaviour of the individual substances of 12 880 was calculated for the absorption maximum at during treatment sessions. Different wavelengths of 325 nm. Purified (purity >98%) furosine was obtained from emission maxima (l em max ) were also observed when Neosystem (Strasbourg, France).
comparing emission spectra of healthy donor serum (l Analysis of pyrraline was performed by amino acid analysis em max at 455 nm), serum from diabetic patients (l using HPLC after prior enzymatic hydrolysis. Enzymatic em max at 444 nm) and aged human serum albumin hydrolysis of plasma samples was performed using four enzymes (pepsin, pronase, aminopeptidase and prolidase) as (l em max at 425 nm). contrast, no fluorescent peaks were detected in the low molecular weight range of plasma samples of healthy controls. As shown in Table 3 , the pre-dialysis peak Molecular weight-specific analysis of fluorescent compounds area of the fraction below 2 kDa was lower in nondiabetics compared with diabetics (1.1±0.9 vs 2.1±2.3); however, the difference was not statistically Typical GPC chromatograms of plasma of a diabetic ESRD patient compared with plasma of a healthy significant (P=0.432). Figure 2 also compares GPC for plasma samples control are given in Figure 2 . Clearly detectable fluorescent peaks were found at mol. wts of~70 and taken at the start and end of treatment. Table 3 summarizes the peak areas for the following fractions14 kDa for both diabetic and non-diabetic uraemic Peaks were grouped into F1-F4 as indicated. Data are given as mean±SD. Please note that post-dialysis data are not corrected for haemoconcentration. aOut of the separation range of the size exclusion column. (<2 kDa) and F4 (peaks beyond the separation capacity of the column). During treatment, the peak area protein) compared with non-diabetic patients (preof the low molecular weight fraction (F3) was reduced dialysis 2.7±0.5, post-dialysis 2.6±0.5 nmol/mg proby~50%, whereas the peak area of the high molecular tein). A non-significant effect of dialysis treatment on weight fractions ( F1 and F2) remained constant. In fructoselysine concentration was observed in both many samples, the low molecular weight fractions were groups. no longer detectable at the end of the treatment period.
The pattern of fluorescent peaks of an ultrafiltrate sample compared with the corresponding plasma Pentosidine sample is shown in Figure 3 . In ultrafiltrates, the No significant differences in plasma pentosidine pattern of fluorescent peaks in the low molecular concentrations were observed between diabetic weight range was similar to that in plasma. The peak (10.0±9.1 pmol/mg protein) and non-diabetic areas significantly decreased during the treatment (9.1±5.1 pmol/mg protein) patients ( Figure 5 ). In period.
non-diabetic patients, only a slight (7±6%) but statistically significant (P<0.05) decrease during dialysis (to Fructoselysine 8.5±4.7 pmol/mg protein) was noted, while a more pronounced (22±29%, P=0.078 diabetic vs nonFructoselysine concentrations in the plasma of diabetic diabetic patients) and significant (P<0.05) decrease and non-diabetic ESRD patients are shown in Figure  ( to 6.8±4.0 pmol/mg protein) was found in diabetic 4. Significantly higher concentrations of the nonpatients. There was a wide scatter of prefluorescent Amadori product fructoselysine were found dialysisconcentrations in both non-diabetic (from 1.5 pre-and post-dialysis in the plasma of diabetic to 18.2 pmol/mg of protein) and diabetic patients (pre-dialysis 3.8±0.8, post-dialysis 3.5±0.7 nmol/mg (from 4.6 to 34.7 pmol/mg of protein). In plasma of healthy donors (n=6), an~10-fold lower mean pento-on the sieving profile of the membrane [25] . Both fluorescence intensity and pentosidine plasma concensidine concentration of 0.9±0.1 pmol/mg protein was found (P<0.01 vs non-diabetic or diabetic patients).
trations decreased during treatment sessions. When analysing total pentosidine in plasma, without differentiating between free and protein-bound pentosiPyrraline dine, we noted a significant reduction during highflux haemodialysis in both non-diabetic and diabetic Pyrraline concentrations were below the limit of detecpatients. The decrease was more pronounced in diation (40 pmol/mg protein) in plasma and ultrafiltrate betic patients. Although the difference did not reach samples of diabetic and non-diabetic patients. The statistical significance (P=0.078), there was a clear theoretical possibility of inhibition by EDTA during tendency for greater removal of pentosidine from enzymatic hydrolysis was excluded by control measureplasma of diabetic patients. This could be explained if ments of heparinized plasma samples.
plasma of diabetic patients contained a higher proportion of free pentosidine and pentosidine bound to low molecular weight peptides, both of which would be Discussion able to permeate high-flux membranes. It is tempting to speculate that the presence of precursors, such as 3-deoxyglucosone (3-DG), which is elevated in diabetic Our study was designed to assess chemically defined early and late products of the Maillard reaction, i.e. patients [24] , or catalytic substances [4] might influence the composition of proteins and peptides modified by fructoselysine, pentosidine and pyrraline, and, in parallel, global fluorescence intensity, in plasma and ultra-the Maillard reaction. In addition, the possibility of differences in release of free and peptide-bound pentosifiltrate of diabetic and non-diabetic patients on highflux dialysis. We confirm elevated total plasma fluores-dine from deep compartments has to be considered.
In order to obtain further insight into the heterogencence and concentrations of the fluorescent late AGE compound pentosidine pre-dialysis, but no difference eity of 'so-called' AGE compounds, we performed size-selective analysis of fluorescent compounds for in plasma concentrations was noted between diabetic and non-diabetic patients [11, 14] . Plasma concentra-all plasma and ultrafiltrate samples obtained from patients. The pattern of fluorescent peaks showed as a tions of pentosidine were 10-fold elevated in uraemic patients when compared with healthy controls. In common characteristic two clearly separated peaks at~70 and~14 kDa, respectively, and a pattern contrast, pre-dialysis concentrations of the Amadori product fructoselysine, a compound formed during the of several peaks below 2 kDa (see Figures 2 and 3) which differed markedly between individual patients. initial stage of the Maillard reaction, were significantly higher in diabetic compared with non-diabetic patients. The most striking difference from healthy controls ( Figure 2 , lower panel ) was observed in the low This difference may indicate that glycaemic control impacts on early Maillard products, while other fac-molecular weight fraction, which was only detectable in uraemic patients, slightly more in diabetic than in tors, e.g. uraemia-associated oxidative or a-dicarbonyl stress, are of greater importance for the late stage of non-diabetic patients. It is tempting to speculate that this fraction below 2 kDa contains mainly pentosidine, the reaction where irreversible cross-linking of proteins occurs [6, 21] .
i.e. as free pentosidine and/or as pentosidine bound to low molecular weight peptides, since nearly the same We also measured pyrraline, a non-fluorescent product formed during the late stage of the Maillard striking difference was observed with respect to the pentosidine concentrations which were 10-fold lower reaction which promotes lysine-cysteine cross-linking and formation of imidazolone, using HPLC methods in plasma of healthy controls. However, measurements of pentosidine concentrations in the different plasma [18] . We were not able to detect pyrraline in plasma samples of patients above the detection limit of 40 fractions are needed to resolve this issue.
A single, clearly delineated fluorescent peak at a pmol/mg protein. The failure to detect pyrraline in uraemic plasma may be due to one or a combination mol. wt of~14 kDa could be identified in plasma of healthy donors and uraemic patients. Only small sigof the following possibilities: (i) the presence of inhibitors in uraemic plasma which block enzymatic hydro-nals with exactly the same retention time were found in the ultrafiltrate samples. By measuring b 2 -microlysis; (ii) rapid receptor binding or degradation of pyrraline; or (iii) rapid interconversion to other prod-globulin (mol. wt 11.8 kDa) in plasma and filtrates, it has been shown that the high-flux membrane used for ucts. Clarification of this this will be particularly interesting, since pyrraline is an important intermediate the treatments is quite permeable for molecules of this molecular weight with a sieving coefficient of~75% product between a-dicarbonyl compounds and imidazolone end-products [22] [23] [24] . [26 ] . Consequently, the plasma concentration of b 2 -microglobulin could be reduced by~65% [27] . The High-flux dialysis entails diffusive and convective mass transfer, and thus provides a convenient proced-data suggest that compounds other than b 2 -microglobulin are represented by this peak and that fast ure to assess whether reactive groups are in filterable low molecular weight or non-filterable high molecu-redistribution occurs between plasma and other compartments. Furthermore, the possibility of interactions lar weight fractions. Isolated ultrafiltration allows the assessment of pure convective mass transfer depending between the separation medium of the GPC column used for molecular weight analysis and modified pro-not include oligopeptide-bound pentosidine. In addition, Miyata's study was performed with cellulosic teins cannot be excluded. This would lead to a delayed elution from the column and thereby to an underes-low-flux membranes which have a limited permeability for substances in the molecular weight range of 2 kDa timation of the molecular weight of the respective compound.
(i.e. vitamin B12 clearance is typically in the range of 50-60 ml/min). In contrast, the high-flux membrane The presence of two fluorescent high molecular weight fractions in plasma of both healthy donors and used in our study is highly permeable in this molecular weight range (i.e. vitamin B12 clearance=144 ml/min) uraemic patients, but the occurrence of fluorescent low molecular weight fractions in uraemic patients only, and our molecular weight-specific analysis shows the presence of fluorescent compounds in the whole range suggests that the accumulation of the latter is of critical importance for AGE-related complications, in agree-of molecular weights below 2 kDa in plasma and ultrafiltrate. ment with reports of Makita et al. [12, 28] . Recently, Fishbane et al. [29] stressed the importance of lowering Many Maillard reaction products are fluorescent, but one must also consider the possible formation of AGE-apoB concentrations, which is the reaction product of reactive intermediates of low molecular weight non-fluorescent products. Fluorescence is not specific for individual compounds; it is a group reactivity AGE compounds with low density lipoproteins and possibly contributes to dyslipidaemia and related accel-which fails to provide quantitative information on concentrations of individual compounds. Nevertheless, eration of arteriosclerosis. Our findings confirm the role of high-flux haemodialysis for an efficient removal the peak areas detected by fluorescence compared prevs post-treatment indicate the relative change in the of AGE compounds. Although high-flux dialysis effectively removes these low molecular weight substances content of fluorescent compounds. The observation of small but significant changes in the emission spectrum of <2 kDa, the efficiency of such intermittent treatment has a limited effect on pre-dialysis values, mainly in plasma samples during dialysis treatment and the significantly larger shift in emission spectrum when because of rapid rebound [14] . More specific removal may be possible in the future by specific sorption comparing plasma and ultrafiltrate samples underlines the heterogeneous chemical nature of fluorescent prodmethods [30-32], but it remains questionable whether they will provide additional therapeutic benefit. ucts, which are probably removed differently during dialysis. Pre-dialysis pentosidine concentrations are lower than those reported by other authors [10, 14] . This
Our study was designed to focus on the simultaneous measurement of chemically defined compounds formed might be due to the pentosidine reference material used in our study. In contrast to isolation procedures in vivo during the Maillard reaction in addition to global assessment by fluorescence and to describe the reported in the literature, the content of our pentosidine isolate was determined by UV measurement and molecular weight-dependent elimination during highflux dialysis. In summary, our investigations revealed elementary analysis. Based on this, a molar absorptivity of 12 880 was calculated for the absorption max-the following novel insights: (i) there are marked differences between pre-dialysis concentrations of variimum at 325 nm, which is significantly higher than the corresponding value of 4195, which was reported previ-ous chemically defined Maillard products and their change during high-flux dialysis; (ii) the time course ously [33] without the results of an elementary analysis and which represents, to our knowledge, the only of concentrations of Maillard reaction products might be different in diabetic and non-diabetic patients due reference for molar absorptivity of pentosidine in the literature. Without control, the use of the lower molar to different molecular weight distributions of modified proteins and peptides and/or due to different rates of absorptivity might have been responsible for an overestimation of pentosidine previously [10, 14] . Sampling release from deep compartments; (iii) the elimination of fluorescent compounds by convection is restricted of plasma was performed according to a strict protocol in order to exclude variations due to the release of to low molecular weight range compounds, suggesting binding to proteins or AGE modification of higher AGE from cell binding sites or cell damage. Plasma concentrations of pentosidine could also be affected by molecular weight substances; and (iv) changes in fluorescence spectra during treatment and differences food intake during dialysis [7] , which was excluded in our study. As a minor factor, the method used between plasma and ultrafiltrate underline the heterogeneous chemical nature of fluorescent AGE which for analysis of protein concentration, i.e. colorimetric measurement of total proteins vs calculation from presumably are eliminated differently during high-flux hemodialysis. Clarification of this point requires amino acid analysis, could lead to differences in plasma concentration, when given in pmol/mg protein.
detailed biochemical analysis of each molecular weight fraction using specific HPLC and mass spectrometry. Renal catabolism and clearance of pentosidine in uraemic patients were analysed recently by Miyata et al. [34] . Our data are basically in agreement, but
